THEA PHARMACEUTICALS LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +14.9%

  £42,141,726 → £48,409,976

  highest in 4 filed years

• Cash

  -62.5%

  £2,317,334 → £869,864

• Net assets

  +7.9%

  £12,234,858 → £13,206,364

  highest in 4 filed years

• Employees

  +3.1%

  64 → 66

  highest in 4 filed years

• Operating profit

  +9.3%

  £3,010,923 → £3,291,899

  highest in 4 filed years

• Profit before tax

  +9.1%

  £3,010,923 → £3,286,284

  highest in 4 filed years

• Wages

  +2.3%

  £4,534,653 → £4,639,971

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. THEA PHARMACEUTICALS LIMITED 2015-01-30 → present
2. SPECTRUM THEA PHARMACEUTICALS LIMITED 2008-04-17 → 2015-01-30
3. SPECTRUM THEA LIMITED 2008-02-15 → 2008-04-17

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Dains Audit Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“At 31 December 2024, the company had net current assets of £13,104,687 (2023 - £12,188,160) and has made a profit in the year of £2,471,506 (2023 £2,243,011). The company is the UK distributor for Laboratoires Thea SAS, its parent company. The Company has received a letter of support from its parent company and have made enquiries of their parent company to satisfy themselves of the parent company's ability to provide financial support. The Directors have prepared forecasts and believe the Company with the financial support of its parent company is able to meet its liabilities as they fall due and consider that is appropriate to prepare the financial statements on a going concern basis as a result.”

Significant events

• “During the year the turnover of the business reached £48.4m, a 15% increase on 2023 turnover of £42.1m. The year on year increase is largely attributed to promotion of core growth products in order to obtain increasing marketing share. The continued high street demand for OTC products, growth of online marketing channels and new product launches have also contributed to the growth of the company.”
• “The company is a member of the new voluntary scheme for branded medicines pricing, access and growth (VPAG) for the years 2024-2028.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.